Former Principal Deputy Commissioner of FDA, Dr. Rachel Sherman, Joins Aptinyx Board of Directors
September 04 2019 - 7:27AM
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, today announced the appointment
of Rachel Sherman, M.D., M.P.H., former principal deputy
commissioner of the U.S. Food and Drug Administration (FDA), to the
company’s Board of Directors, effective immediately.
“Rachel’s expertise in drug development, evaluation, and
regulation is unparalleled and we are honored to welcome her to our
Board of Directors,” stated Norbert Riedel, Ph.D., president and
chief executive officer of Aptinyx. “During her extraordinary
tenure at the FDA, across various divisions and senior-level roles,
Rachel has been instrumental in many efforts that have led to
remarkable improvements in drug development. The relationships,
skills, and insights garnered throughout her exemplary career will
add a unique domain expertise and perspective to our Board.”
Dr. Sherman, a renowned expert in medical policy, served at the
FDA for nearly 30 years until her retirement early in 2019. Most
recently at the FDA, she was the principal deputy commissioner—the
commissioner’s most senior policy advisor and the agency’s highest
position not politically appointed. Dr. Sherman held this position
from 2017 until her retirement. Additional senior-level roles she
held while at the FDA included deputy commissioner for Medical
Products and Tobacco in the Office of the Commissioner and director
of the Office of Medical Policy in the Center for Drug Evaluation
and Research (CDER). During her time with the Agency, Dr. Sherman
played lead roles in numerous policy and organizational initiatives
credited with enhancing product development and facilitating
patient access to innovative medicines, including expedited drug
development and breakthrough therapy designation programs as well
as the Opioid Policy Steering Committee.
“I am delighted to be joining the exemplary team of dedicated
professionals at Aptinyx,” said Dr. Sherman. “The company’s NMDA
receptor platform, rooted in novel chemistry and a unique mechanism
for modulation of a critical regulator of brain and nervous system
function, has yielded a product pipeline with significant
therapeutic potential to help patients without satisfactory
options. CNS is an area starved for innovation, marked by an opioid
crisis that is devastating the United States, and in which new
therapeutic options are desperately needed. I am excited to be able
to participate in the progression of Aptinyx’s promising product
candidates for the treatment of devastating CNS conditions.”
Dr. Sherman is currently president of Rachel Sherman Partners
LLC, a drug development, regulatory, and policy consulting firm she
founded in 2019 following her retirement from the FDA. She also
serves as a clinical lecturer at Harvard Pilgrim Health Care
Institute and as a senior policy fellow at Duke University’s
Margolis Center for Health Policy.
Dr. Sherman received an A.B. in mathematics from Washington
University (St. Louis), an M.D. from Mount Sinai School of
Medicine, and an M.P.H. from The School of Hygiene and Public
Health at Johns Hopkins University.
About AptinyxAptinyx Inc. is a
clinical-stage biopharmaceutical company focused on the discovery,
development, and commercialization of proprietary synthetic small
molecules for the treatment of brain and nervous system
disorders. Aptinyx has a platform for discovery of novel
compounds that work through a unique mechanism to modulate—rather
than block or over-activate—NMDA receptors and enhance synaptic
plasticity, the foundation of neural cell communication. The
company has three product candidates in clinical development in
central nervous system indications, including chronic pain,
post-traumatic stress disorder, and cognitive impairment associated
with Parkinson’s disease. Aptinyx is also advancing
additional compounds from its proprietary discovery platform, which
continues to generate a rich and diverse pipeline of small-molecule
NMDA receptor modulators with the potential to treat an array of
neurologic disorders. For more information,
visit www.aptinyx.com.
Forward-Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not
limited to, statements regarding the company’s business plans and
objectives, including future plans or expectations for the
company’s product candidates, therapeutic effects of the company’s
product candidates, expectations regarding the design,
implementation, timing, and success of its current and planned
clinical studies, and expectations regarding its uses and
sufficiency of capital. Risks that contribute to the uncertain
nature of the forward-looking statements include: the success,
cost, and timing of the company’s product candidate development
activities and planned clinical studies; the company’s ability to
execute on its strategy; positive results from a clinical study may
not necessarily be predictive of the results of future or ongoing
clinical studies; regulatory developments in the United States and
foreign countries; as well as those risks and uncertainties set
forth in the company’s most recent Annual Report on Form 10-K and
subsequent filings with the Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Aptinyx undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Investor & Media Contact:Nick SmithAptinyx
Inc.ir@aptinyx.com or corporate@aptinyx.com847-871-0377
Source: Aptinyx Inc.
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Apr 2023 to Apr 2024